CN114555056A - 小分子PI4KIIIα抑制剂组合物、其制备方法及用途 - Google Patents

小分子PI4KIIIα抑制剂组合物、其制备方法及用途 Download PDF

Info

Publication number
CN114555056A
CN114555056A CN202080049288.5A CN202080049288A CN114555056A CN 114555056 A CN114555056 A CN 114555056A CN 202080049288 A CN202080049288 A CN 202080049288A CN 114555056 A CN114555056 A CN 114555056A
Authority
CN
China
Prior art keywords
pharmaceutical composition
oil
pao
pi4kiii
lipid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN202080049288.5A
Other languages
English (en)
Other versions
CN114555056B (zh
Inventor
黄福德
王峰
杨书
焦常平
周小军
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nobetide Pharmaceutical Technology Shanghai Co ltd
Original Assignee
Nobetide Pharmaceutical Technology Shanghai Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nobetide Pharmaceutical Technology Shanghai Co ltd filed Critical Nobetide Pharmaceutical Technology Shanghai Co ltd
Publication of CN114555056A publication Critical patent/CN114555056A/zh
Application granted granted Critical
Publication of CN114555056B publication Critical patent/CN114555056B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/285—Arsenic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin

Abstract

一种药物组合物，所述药物组合物包含小分子PI4KIIIα抑制剂和药学上可接受的载体，其中所述药学上可接受的载体包括脂质。还公开了制备所述药物组合物的方法，以及使用所述药物组合物治疗PI4KIIIα相关疾病的方法。

Description

PCT国内申请，说明书已公开。

Claims (43)

  1. PCT国内申请，权利要求书已公开。
CN202080049288.5A 2019-07-05 2020-07-06 小分子PI4KIIIα抑制剂组合物、其制备方法及用途 Active CN114555056B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNPCT/CN2019/094831 2019-07-05
CN2019094831 2019-07-05
PCT/CN2020/100377 WO2021004422A1 (zh) 2019-07-05 2020-07-06 小分子PI4KIIIα抑制剂组合物、其制备方法及用途

Publications (2)

Publication Number Publication Date
CN114555056A true CN114555056A (zh) 2022-05-27
CN114555056B CN114555056B (zh) 2024-01-05

Family

ID=74115038

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080049288.5A Active CN114555056B (zh) 2019-07-05 2020-07-06 小分子PI4KIIIα抑制剂组合物、其制备方法及用途

Country Status (14)

Country Link
US (1) US20230115711A1 (zh)
EP (1) EP3995134A4 (zh)
JP (1) JP2022538505A (zh)
KR (1) KR20220071175A (zh)
CN (1) CN114555056B (zh)
AU (1) AU2020309681A1 (zh)
BR (1) BR112022000155A2 (zh)
CA (1) CA3149104A1 (zh)
CO (1) CO2022001218A2 (zh)
IL (1) IL289586A (zh)
MX (1) MX2022000287A (zh)
PE (1) PE20220942A1 (zh)
TW (1) TW202126294A (zh)
WO (1) WO2021004422A1 (zh)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114685566A (zh) * 2020-12-31 2022-07-01 江苏挪贝肽医药科技有限公司 氧化苯砷晶型i、晶型ii和晶型iii及其制备方法
CA3233744A1 (en) * 2021-09-30 2023-04-06 Nuo-Beta Pharmaceutical Technology (Shanghai) Co., Ltd. Halogenated phenylarsine oxide compound and application thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101688206A (zh) * 2007-07-05 2010-03-31 诺瓦提斯公司 用于靶向病毒感染的dsRNA
WO2016172952A1 (zh) * 2015-04-30 2016-11-03 江苏挪贝肽医药科技有限公司 PI4KIIIα蛋白及相关的膜蛋白复合体在治疗阿尔茨海默病中的应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030032203A1 (en) * 2001-07-10 2003-02-13 Sabatini David M. Small molecule microarrays
JP2021521279A (ja) * 2018-04-11 2021-08-26 ニュー メキシコ テック ユニバーシティ リサーチ パーク コーポレーション 薬物送達における使用のための脂質プロドラッグ

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101688206A (zh) * 2007-07-05 2010-03-31 诺瓦提斯公司 用于靶向病毒感染的dsRNA
WO2016172952A1 (zh) * 2015-04-30 2016-11-03 江苏挪贝肽医药科技有限公司 PI4KIIIα蛋白及相关的膜蛋白复合体在治疗阿尔茨海默病中的应用

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
戚建平等: "脂质纳米粒在口服给药***中的应用" *

Also Published As

Publication number Publication date
CA3149104A1 (en) 2021-01-14
IL289586A (en) 2022-03-01
AU2020309681A1 (en) 2022-02-24
EP3995134A4 (en) 2023-07-12
CO2022001218A2 (es) 2022-05-20
EP3995134A1 (en) 2022-05-11
TW202126294A (zh) 2021-07-16
KR20220071175A (ko) 2022-05-31
BR112022000155A2 (pt) 2022-04-12
JP2022538505A (ja) 2022-09-02
US20230115711A1 (en) 2023-04-13
WO2021004422A1 (zh) 2021-01-14
MX2022000287A (es) 2022-06-16
CN114555056B (zh) 2024-01-05
PE20220942A1 (es) 2022-05-31

Similar Documents

Publication Publication Date Title
JP2019519556A (ja) カンナビノイド製剤
KR20200106049A (ko) 칸나비노이드 및 폴록사머를 포함하는 경구 약학 제형
CA2866067C (en) Uses of certain f-series prostaglandin analogs for treating diabetes and dyslipidemia
KR20170008311A (ko) 안정한 카나비노이드 제형
KR101651448B1 (ko) 체지방을 국소적으로 증가시키는 방법 및 조성물
JP2014513094A (ja) 親油性医薬用薬剤の改良された非経口製剤ならびにそれを調製および使用するための方法
AU2021269396A1 (en) Very-long-chain polyunsaturated fatty acids, elovanoid hydroxylated derivatives, and methods of use
CN114555056B (zh) 小分子PI4KIIIα抑制剂组合物、其制备方法及用途
JP2021120388A (ja) 神経保護および神経変性の治療のための組成物および方法
CN113336768B (zh) 一种多靶点酪氨酸激酶抑制剂
EP2528598B1 (en) Compounds for suppressing a peripheral nerve disorder induced by an anti - cancer agent
CN108309935B (zh) 一种紫檀芪类化合物心肌靶向制剂及其应用
AU2008326593A1 (en) Pyrazolone derivative emulsion formulations
OA20568A (en) Micromolecule PI4Klllα inhibitor composition, preparation method therefor and use thereof.
JP6473801B2 (ja) １３種のグリセリド含む医薬組成物、製剤及びその応用
CN109985004A (zh) 氟比洛芬酯脂肪乳注射液、其制备方法及应用
US11707467B2 (en) (17-ß)-3-oxoandrost-4-en-17YL tridecanoate compositions and methods of their preparation and use
CN109438321B (zh) 一种色氨酸衍生物及其制备方法和应用
WO2017047618A1 (ja) ラパマイシン又はその誘導体を含有する医薬組成物
JP2023540664A (ja) Ｉｒａｋ４阻害剤及びそれらの局所的使用方法
JP2023551415A (ja) カンナビジオールの固体分散体
WO2021026413A1 (en) Pharmaceutical composition for use in the treatment of neurological diseases
AU2018219810A1 (en) Solid fosmetpantotenate formulations

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40074190

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant